428 results on '"Tougeron, D."'
Search Results
2. Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)
3. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
4. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability
5. Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study
6. CO170 Treatment Exposure-Adjusted Event Rates (EAERs) for Grade 3/4 AEs Associated with Emerging and Existing Systemic Therapies for mCRC with at Least 2 Prior Lines of Therapy: Informing Payer and Pathway Formulary Decision Making
7. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer
8. 608P Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort
9. Intra peritoneal abdominal fat area measured from computed tomography is an independent factor of severe acute pancreatitis
10. Circulating tumor DNA at baseline for individualized prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study
11. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
12. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
13. OC-0277 Capecitabine or 5-fluorouracil infusion with radiotherapy of anal cancers in the FFCD-Anabase cohort
14. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
15. Électroporation irréversible du cancer du pancréas
16. Irreversible electroporation for locally advanced pancreatic cancer
17. 139P Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
18. EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French Perspective
19. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)
20. 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)
21. 86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
22. LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial
23. 365P Prognostic value of Lynch syndrome, BRAFV600E and RAS mutation status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of the national Dutch and French cohorts
24. 449TiP Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study
25. 429P Management of localized anal cancer and prognostic factors in the elderly: Results of the French multicenter cohort FFCD – ANABASE
26. O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
27. Lichenoid eruption during antiPD-L1 immunotherapy with avelumab in metastatic colorectal cancer
28. OC-0270 Final results of the French national cohort ANABASE : treatment and outcome in anal cancer
29. MO-0226 Clinical outcomes of HIV-positive patients with anal cancer in the ANABASE multicentric cohort
30. Deep Treatment Response Assessment and Prediction of Colorectal Cancer Liver Metastases
31. Management of esophageal adenocarcinoma
32. Traitement des adénocarcinomes de l’œsophage
33. Efficacité et toxicité de la (chimio)radiothérapie chez les patients séropositifs pour le VIH atteints d’un carcinome épidermoïde du canal anal, analyse en sous-groupe de la cohorte multicentrique Anabase
34. 425P Cetuximab could be administered once every two weeks instead of once weekly
35. 508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
36. 438P First line treatment patterns in BRAFV600E-mutant metastatic colorectal cancer patients (mCRC): The CAPSTAN European retrospective study
37. 1472P Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
38. 462P Heterogeneity of mismatch repair status between primary tumors and matched metastases in metastatic colorectal cancer
39. 66P Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC).
40. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study
41. P-51 Baseline characteristics of patients enrolled in the CAPSTAN study: A European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients
42. 731P REWENEC: REal-World Evidence in NEC provides a reliable external control arm to avoid randomization for second-line clinical trials - A post hoc proof of concept analysis with the randomized phase II BEVANEC study
43. 650P Genomic profiling of small bowel adenocarcinoma: A pooled analysis
44. 1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
45. 629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
46. 625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
47. 1555P Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study
48. 1520P Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial
49. 121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
50. 119P Management of biliary tract cancers in older patients: A French multicenter cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.